Healthcare with Confidence
A Personalized Roadmap for Smarter Cancer Treatment
If you or a loved one has already been diagnosed with cancer, one of the hardest parts is understanding what to do next.
Many patients are told about one treatment plan, but they still want to know whether there are additional options, more advanced tests, or clinical trials that could be relevant to their case. That is where Cancer PreScreening in Israel can help.
In this context, cancer prescreening is not screening for healthy people. It is a personalized expert review after diagnosis that helps patients and families understand the full treatment picture: what has already been done, which standard options remain, whether biomarker or genomic testing is needed, and whether targeted therapy, immunotherapy, or a clinical trial may be appropriate.
Biomarker testing is now a central part of precision oncology, and clinical-trial matching often depends on details such as tumor type, stage, prior treatment, and specific genetic changes.
What is Cancer PreScreening?
Cancer PreScreening is a structured medical review designed to give you a clearer and more personalized treatment roadmap. Instead of looking only at one current recommendation, it reviews your diagnosis more broadly and asks important questions:
- Is the diagnosis complete and fully confirmed?
- Have all standard treatment options been considered?
- Are there important biomarkers or molecular tests still missing?
- Could there be a targeted therapy or immunotherapy option?
- Are there clinical trials that match this exact tumor profile?
This approach reflects how modern oncology increasingly works today. The National Cancer Institute describes biomarker testing as a way to look for genes, proteins, and other tumor markers that can help doctors choose treatment, and ESMO’s updated precision-medicine recommendations support tumor NGS in several advanced cancers, including advanced non-squamous NSCLC, prostate, colorectal, cholangiocarcinoma, and ovarian cancer.
Why Cancer PreScreening matters more today than before
Cancer treatment is no longer based only on where the tumor started. Today, some therapies are chosen according to the tumor’s molecular profile, not just the organ involved. The NCI notes that precision medicine uses genes, proteins, and other biomarkers to tailor care, and FDA-recognized tumor-agnostic treatment pathways now exist for certain biomarkers across different cancer types.
Examples of currently recognized biomarker-driven or tumor-agnostic options include:
- pembrolizumab for certain MSI-H/dMMR solid tumors
- pembrolizumab for certain TMB-high solid tumors
- larotrectinib or repotrectinib for NTRK fusion-positive tumors
- selpercatinib for RET fusion-positive solid tumors
- dabrafenib + trametinib for BRAF V600E solid tumors in the approved setting
- trastuzumab deruxtecan for certain HER2-positive (IHC 3+) solid tumors after prior treatment
This does not mean every patient needs these drugs or qualifies for them. It means that a patient may miss important options if the tumor has not been properly reviewed at the biomarker and genomic level. That is why a prescreening step can be so valuable before changing treatment, traveling for care, or assuming that “nothing else is available.”
What Personalized Cancer PreScreening in Israel can give you
A strong prescreening process should help create a practical and understandable treatment map. For many patients, that includes:
1. A full review of your current medical situation
This includes diagnosis, pathology, stage, prior treatments, treatment response, and the current clinical question. It helps patients understand whether standard options have truly been exhausted or whether important established treatments still remain. Biomarker testing and treatment selection are most useful when interpreted in the context of the full disease history.
2. A clearer plan for genomic and biomarker testing
Not every patient needs every test. In modern oncology, the right testing strategy depends on the tumor type, stage, available tissue, prior therapy, and the treatment decisions that still need to be made. ESMO’s updated recommendations support broader NGS in some advanced cancers, while the FDA also maintains a current list of approved companion diagnostics that are essential for the safe and effective use of certain cancer therapies.
3. Better understanding of treatment options beyond one standard protocol
Prescreening may help identify:
- targeted therapies
- immunotherapy options
- combinations already approved in other settings
- treatment pathways linked to specific biomarkers
- relevant clinical trials
The NCI and FDA both emphasize that biomarker testing can guide treatment selection, and clinical trial eligibility often depends on genetic alterations, previous therapies, and other disease-specific criteria.
4. A more rational way to decide on next steps
For many families, the value of prescreening is not only in finding “something new,” but in replacing uncertainty with a structured plan. That plan may confirm the current treatment, recommend additional pathology or genomic review, or identify realistic options in Israel or through trial programs.
Genomic testing: which tests may matter?
One of the most important parts of modern cancer prescreening is deciding which tests are worth doing. This may include:
- tumor biomarker testing
- next-generation sequencing (NGS)
- broader comprehensive genomic profiling
- selected immunohistochemistry tests
- liquid biopsy in appropriate cases
The NCI explains that biomarker testing can look for genes, proteins, and other features that affect treatment choice. Liquid biopsy can also be useful when tumor tissue is limited, a tumor is hard to reach, or repeat monitoring is needed.
For patients with advanced cancer, the test itself matters because some therapies require a validated companion diagnostic. The FDA states that a companion diagnostic provides information essential for the safe and effective use of a corresponding therapy.
Why Israel is attractive for cancer prescreening and second opinion
Israel is well known for combining multidisciplinary oncology care, advanced diagnostics, and access to precision-medicine thinking. Publicly available information from major Israeli centers shows this trend clearly: Ichilov describes comprehensive multidisciplinary cancer care for patients from Israel and abroad, while Hadassah has publicly described an integrated model using comprehensive genomic profiling to support precise, disease-targeted treatment and trial access.
For international patients, this can be especially helpful when they need:
- a fast expert second opinion
- review of pathology and scans
- advice on molecular testing
- evaluation of advanced treatment options
- help understanding whether travel for treatment is justified
Who can benefit most from Cancer PreScreening?
Cancer PreScreening in Israel may be especially useful for patients who:
- have recurrent or metastatic cancer
- were told that standard treatment options are limited
- want to know whether more precise testing is missing
- are looking for targeted therapy or immunotherapy options
- want to explore clinical trials
- have a rare tumor, unclear pathology, or conflicting recommendations
This is also valuable for patients who simply want to make sure that nothing important has been overlooked before starting the next line of treatment. In today’s oncology landscape, missed biomarkers can mean missed opportunities.
What to send for a Cancer PreScreening review
To build a meaningful personalized roadmap, patients usually need to send:
- pathology report
- biopsy results
- molecular or genomic test results, if already done
- CT, PET-CT, MRI, or other imaging reports
- treatment summary with dates
- current medication list
- recent blood tests, when relevant
- short summary of the current clinical question
This matches how modern trial and biomarker decisions are made: the NCI notes that trial matching often requires details about cancer type, stage, prior treatment, genetic findings, age group, medical history, and current health status.
What happens after the prescreening?
A good prescreening result should not be just a list of drug names. It should give you a clear written strategy. That may include:
- what standard treatments remain
- whether additional pathology review is needed
- which biomarkers should be checked
- whether NGS or liquid biopsy is appropriate
- whether any approved targeted or immune options may be relevant
- whether a clinical trial search should be prioritized
- whether treatment in Israel makes practical sense
The goal is simple: to help patients move from confusion to a more informed treatment decision, based on current precision-oncology principles rather than guesswork alone.
Cancer PreScreening in Israel: a patient-friendly summary
Personalized Cancer PreScreening in Israel can help you understand not only what your cancer is, but also what may still be possible. Today cancer care is increasingly guided by biomarkers, companion diagnostics, tumor genomics, and trial eligibility. For some patients, this confirms the current plan. For others, it opens doors to options that were not discussed before.
If you are facing a difficult cancer decision and want a clearer view of standard treatment, personalized testing, innovative therapies, and possible clinical studies, Cancer PreScreening in Israel can be a practical first step.
Need a personalized cancer treatment roadmap?
Send your medical files for expert review and find out which standard, molecular, and advanced treatment options may be relevant for your case.
